Fondation Bill & Melinda Gates

Accelerating the discovery of non-hormonal human contraceptives is one of the “Grand Challenges” programs launched by the Bill & Melinda Gates Foundation for the years to come. A research project, funded to the tune of 1.8 M USD, carried out by a consortium led by INRAE, including IN-CELL-ART, a French biotechnology company specializing in nanotransporter technologies called NANOTAXI®, the Italian university UNIMORE, and MAbSilico, a start-up from INRAE ​​offering software based on Artificial Intelligence technologies for the development of antibodies, has just started as part of this program. The objective is to design biological products based on antibody fragments to block ovulation and thus constitute a non-hormonal contraceptive with fewer side effects.

More information here